persist
west
nile
viru
wnv
infect
throughout
usa
sinc
incept
continu
spread
throughout
globe
call
urgent
need
effect
treatment
prevent
measur
although
licens
sever
wnv
vaccin
veterinari
use
provid
proof
concept
similar
effort
develop
effect
vaccin
human
remain
still
unsuccess
increas
understand
biolog
pathogenesi
wnv
togeth
recent
technolog
advanc
rais
hope
effect
wnv
vaccin
may
avail
near
futur
addit
rapid
progress
structur
function
character
wnv
fl
avivir
protein
provid
solid
base
design
develop
sever
class
inhibitor
potenti
wnv
therapeut
moreov
therapeut
monoclon
antibodi
demonstr
excel
effi
caci
wnv
anim
model
repres
promis
class
wnv
therapeut
howev
challeng
design
develop
safe
effi
cient
wnv
vaccin
therapeut
chapter
discuss
current
approach
progress
challeng
toward
develop
wnv
vaccin
therapeut
antibodi
antivir
drug
may
caus
injuri
death
neuron
variou
clinic
manifest
enceph
mening
fl
accid
paralysi
persist
neurolog
sequela
possibl
death
particularli
elderli
immunocompromis
individu
wnv
strongli
activ
host
immun
respons
play
import
role
control
viremia
viral
dissemin
central
nervou
system
cn
recoveri
diseas
howev
mechan
wnv
pathogenesi
includ
tropism
neuron
cn
invas
viral
host
factor
contribut
imbal
viral
patholog
host
immun
still
remain
poorli
understood
although
wnv
fi
rst
discov
uganda
consid
minor
public
health
concern
fi
rst
appear
usa
sinc
dramat
spread
continent
state
usa
becam
endem
diseas
throughout
north
america
within
year
usa
alon
report
case
wnv
classifi
ed
neuroinvas
claim
live
nearli
two
thousand
peopl
howev
actual
wnv
burden
like
much
higher
previous
thought
infect
individu
develop
clinic
wnv
diseas
estim
three
million
individu
infect
wnv
usa
symptomat
diseas
wnv
also
potenti
develop
unusu
clinic
manifest
may
involv
renal
diseas
myasthenia
gravi
myocard
suggest
rang
sever
wnv
diseas
may
even
wors
previous
believ
importantli
increas
number
wnv
outbreak
last
year
associ
greater
number
neuroinvas
case
higher
rate
fatal
howev
vaccin
antivir
therapeut
current
avail
limit
current
treatment
support
care
measur
intraven
fl
uid
antipyret
respiratori
support
prevent
secondari
infect
consid
worldwid
distribut
viru
evid
potenti
chang
pathogen
transmiss
urgent
need
develop
safe
effect
antivir
drug
vaccin
wnv
infect
intens
research
past
decad
made
signifi
cant
progress
design
develop
sever
treatment
prevent
method
wnv
infect
review
discuss
current
approach
recent
progress
toward
develop
vaccin
therapeut
antibodi
antivir
drug
wnv
infect
human
wnv
spheric
viru
nm
diamet
compris
icosahedr
nucleocapsid
surround
lipid
envelop
viru
contain
singlestrand
cap
plussens
rna
genom
approxim
kb
size
viral
genom
encod
polyprotein
precursor
undergo
posttransl
process
cellular
viral
proteas
gener
three
structur
protein
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
structur
protein
form
virion
structur
wherea
nonstructur
protein
play
essenti
role
replic
viral
genom
assembl
virion
viral
pathogenesi
thu
structur
nonstructur
protein
wnv
may
potenti
target
develop
vaccin
antivir
therapeut
tabl
wnv
virion
structur
c
protein
encapsul
viral
genom
rna
form
nucleocapsid
envelop
lipid
bilay
trimmer
prme
heterodim
form
spikelik
project
among
structur
protein
e
protein
mediat
crucial
role
bind
cellular
receptor
membran
fusion
entri
wnv
host
cell
make
key
target
develop
vaccin
neutral
antibodi
entri
inhibitor
crystal
structur
analysi
confi
rmed
e
protein
fold
three
structur
distinct
ectodomain
ed
term
edi
edii
ediii
among
ediii
consist
major
neutral
epitop
antigen
choic
elicit
product
neutral
antibodi
base
structur
character
antifl
avivir
monoclon
antibodi
human
nonhuman
primat
appear
epitop
fl
avivir
e
protein
complex
divers
previous
thought
addit
map
bcell
tcell
epitop
led
identifi
cation
mani
immunodomin
epitop
structur
nonstructur
protein
wnv
among
nonstructur
protein
bestcharacter
multifunct
protein
contain
enzymat
activ
essenti
viral
replic
enzymat
function
receiv
consider
attent
potenti
target
antivir
drug
develop
protein
contain
two
distinct
function
domain
ntermin
domain
amino
acid
residu
serin
proteas
activ
requir
polypeptid
cofactor
activ
recent
xray
crystallograph
studi
shown
conform
control
substrat
bind
proteas
contrast
ctermin
domain
function
rna
helicas
besid
function
viral
replic
also
play
role
viral
pathogenesi
antagon
host
interferon
respons
nonstructur
protein
form
scaffold
viral
replic
complex
also
role
replic
viral
genom
host
immun
evas
mutat
protein
may
attenu
wnv
fl
avivirus
addit
recent
success
clinic
trial
hepat
c
viru
inhibitor
suggest
target
nonstructur
protein
may
ideal
strategi
develop
therapeut
fl
avivirus
includ
wnv
particular
ctermin
ediii
e
protein
contain
critic
neutral
epitop
major
target
neutral
antibodi
wnv
infect
addit
humor
immun
respons
cell
mediat
immun
cell
play
critic
role
recoveri
wnv
infect
thu
effi
cient
gener
vaccineinduc
immun
wnv
may
also
requir
activ
shape
multipl
effector
adapt
immun
respons
earli
innat
signal
pathway
develop
effect
vaccin
requir
multipl
step
design
develop
rigor
evalu
safeti
effi
caci
fig
sinc
biolog
vaccineinduc
immun
principl
vaccin
develop
test
extens
discuss
discuss
topic
immun
laboratori
anim
subsequ
challeng
anim
pathogen
control
condit
common
method
earli
evalu
vaccin
effect
introduct
three
mutat
respons
attenu
jev
equival
posit
wnv
e
gene
attenu
similarli
vaccin
candid
attenu
delet
untransl
region
utr
viral
genom
engin
express
prm
e
preclin
evalu
mice
gees
monkey
show
strong
immunogen
clinic
trial
addit
chimer
vaccin
candid
express
wnv
prm
e
protein
shown
protect
mice
infect
wnv
strain
anoth
recombin
wnv
vaccin
base
infl
uenza
vaccin
flunadiii
develop
clone
diii
wnv
e
ntermin
region
neuraminidas
infl
uenza
viru
vaccin
candid
induc
wnvspecifi
c
neutral
igg
protect
mice
lethal
wnv
infect
similarli
recombin
adenovir
vaccin
vector
cadvaxwnvii
express
three
structur
protein
c
prm
e
along
wnv
induc
neutral
antibodi
mice
common
approach
develop
nonrepl
inactiv
viral
vaccin
inactiv
entir
viru
particl
use
chemic
formalininactiv
wnv
vaccin
base
strain
fi
rst
success
veterinari
vaccin
market
pfi
zer
west
nile
innov
licens
anoth
veterinari
wnv
vaccin
use
kill
viru
also
licens
usda
market
boehring
ingelheim
wnv
recent
inactiv
wnv
vaccin
wnvax
base
wnv
protect
mice
lethal
wnv
infect
exhibit
immunogen
monkey
addit
wnv
formalin
inactiv
wnv
strain
induc
neutral
antibodi
protect
immun
gees
altern
tradit
formalinbas
vaccin
novel
hydrogen
peroxid
h
inactiv
approach
recent
use
produc
wholeviru
vaccin
wnv
mice
immun
h
inactiv
wnv
vaccin
candid
develop
high
serum
neutral
titer
offer
complet
protect
vaccin
mice
lethal
wnv
challeng
one
h
inactiv
vaccin
recent
introduc
phase
clinic
trial
although
inactiv
virul
wnv
viru
strain
success
achiev
chemicalinactiv
method
use
natur
attenu
kunjin
strain
wnv
chemic
synthes
viru
cdna
system
start
materi
also
propos
sever
studi
demonstr
solubl
recombin
protein
vlp
base
approach
could
serv
develop
wnv
vaccin
vlp
special
subvir
particl
lack
viral
genom
sole
contain
viral
structur
protein
express
viral
protein
envelop
membran
differ
vector
product
system
evalu
develop
variou
subunit
vaccin
wnv
exampl
recombin
truncat
form
wnv
e
protein
produc
escherichia
coli
induc
neutral
antibodi
protect
mice
lethal
wnv
challeng
addit
recombin
truncat
wnv
e
protein
produc
sf
insect
cell
via
baculoviru
infect
induc
neutral
antibodi
protect
mice
hamster
wnv
infect
recombin
baculoviru
also
use
express
wnv
prm
e
protein
mammalian
cell
cmv
promot
without
vesicular
stomat
viru
glycoprotein
bacgprm
vaccin
induc
robust
immun
respons
inocul
mice
produc
neutral
antibodi
infl
ammatori
cytokin
recent
propos
novel
approach
known
pseudotyp
retroviru
gag
polyprotein
form
vlp
scaffold
display
ectodomain
human
membran
glycoprotein
fuse
high
affi
niti
ige
receptor
gamma
chain
rige
use
retroviru
base
vlp
platform
wnv
vaccin
gener
replac
ectodomain
glycoprotein
ediii
wnv
induc
neutral
antibodi
mice
recombin
e
protein
produc
drosophila
cell
develop
hawaii
biotech
wnv
subunit
vaccin
candid
test
phase
clinic
trial
although
preclin
studi
reveal
wnvspecifi
c
neutral
antibodi
respons
vaccin
anim
immunogen
vaccin
human
low
increas
immunogen
conjug
recombin
protein
nanoparticl
pathogen
associ
molecular
pattern
pamp
carrieradjuv
test
instanc
recombin
wnv
e
protein
administ
unmethyl
cpg
oligonucleotid
adjuv
load
onto
cpgmodifi
ed
nanoparticl
strongli
activ
dendrit
cell
lymphocyt
elicit
immun
respons
produc
high
titer
immun
mice
similarli
mice
inject
diii
wnv
e
conjug
bacteri
fl
agellin
vlp
deriv
bacteriophag
engin
express
diii
wnv
e
also
signifi
cantli
increas
neutral
antibodi
product
protect
immun
mice
despit
intens
effort
develop
wnv
vaccin
reach
clinic
trial
stage
clinic
trial
candid
vaccin
fail
demonstr
effi
cient
immun
safeti
develop
new
tool
antigen
screen
expand
understand
immunolog
correl
vaccin
inducedimmun
discoveri
novel
adjuv
vaccin
deliveri
may
facilit
design
develop
wnv
vaccin
exampl
knowledg
genom
inform
bioinformat
use
silico
identifi
cation
candid
antigen
develop
vaccin
novel
method
call
revers
vaccinolog
comprehens
tool
quickli
identifi
potenti
antigen
code
genom
may
use
develop
novel
viral
vaccin
develop
vaccin
group
b
streptococci
prove
potenti
approach
similarli
structur
approach
improv
antigen
vaccin
ration
design
develop
util
knowledg
immunolog
structur
biolog
bioinformat
addit
increas
understand
immunogenet
role
environment
host
factor
determin
variat
vaccin
immun
may
offer
new
approach
design
effect
vaccin
wnv
infect
human
therapeut
monoclon
antibodi
mab
hyperimmun
sera
success
use
prophylaxi
number
infecti
noninfecti
diseas
includ
wnv
infect
recent
year
number
mab
preclin
develop
clinic
trial
increas
signifi
cantli
far
nearli
mab
approv
therapeut
us
fda
includ
human
mab
synagi
palivizumab
prevent
use
respiratori
syncyti
viru
wnv
infect
induc
potent
humor
immun
respons
essenti
control
viremia
limit
wnv
dissemin
cn
hyperimmun
sera
globulin
affi
nitypurifi
ed
antibodi
harvest
wnvinfect
human
anim
protect
wildtyp
immunocompromis
mice
wnv
challeng
laboratori
condit
addit
wnv
patient
receiv
antibodi
wnv
seroposit
donor
recov
wnv
infect
studi
encourag
effort
toward
develop
human
human
monoclon
antibodi
wnv
also
led
discoveri
sever
potent
monoclon
antibodi
show
effi
cient
protect
mice
hamster
wnv
infect
among
human
antiwnv
mab
bind
highli
conserv
epitop
wnv
e
protein
block
viral
fusion
provid
postexposur
therapeut
potenti
antibodi
current
assess
potenti
use
wnv
therapeut
antibodi
phase
clinic
trial
show
anoth
human
recombin
antibodi
target
e
protein
wnv
known
good
safeti
toler
profi
le
healthi
human
howev
phase
ii
trial
assess
effi
caci
wnv
infect
fail
due
poor
enrol
particip
besid
develop
whole
antibodi
recombin
fusion
protein
also
gener
singlechain
antibodi
fragment
variabl
region
antibodi
fragment
target
e
protein
may
potenti
candid
immunoprophylaxi
therapi
wnv
infect
recombin
human
singlechain
variabl
region
antibodi
fragment
fvfc
fusion
protein
protect
role
wnv
infect
mice
one
potenti
limit
approach
antibodydepend
enhanc
ade
phenomenon
infect
virus
enhanc
virusreact
antibodi
result
effi
cient
viru
entri
fc
receptormedi
pathway
phenomenon
play
role
patholog
sever
dengu
infect
also
observ
wnv
vitro
although
role
ade
wnv
diseas
unclear
develop
therapeut
antibodi
wnv
address
potenti
issu
anoth
limit
antibodybas
therapeut
high
product
cost
limit
mab
scalabl
produc
therapeut
protein
includ
antibodi
plant
may
promis
solut
feasibl
approach
affi
rmed
success
product
antiwnv
monoclon
antibodi
plant
nicotiana
benthamiana
plantderiv
confer
potent
neutral
activ
vitro
without
ade
effi
cientli
bind
complement
fc
receptor
protect
mice
lethal
wnvchalleng
similar
potenc
mammaliancel
counterpart
antibodi
employ
sever
mechan
control
wnv
viral
infect
includ
blockag
viral
entri
fcdepend
viral
clearanc
complementmedi
viral
lysi
antibodydepend
cytotox
infect
cell
current
research
develop
therapeut
antibodi
wnv
design
test
effi
cient
neutral
potenti
increas
understand
biolog
antibodi
fc
region
particular
role
glycan
fc
mediat
function
may
facilit
design
develop
highqual
antibodi
glycoengin
engin
antibodi
fc
region
may
use
overcom
ade
modul
pharmacokinet
enhanc
fc
mediat
effector
function
enhanc
antibodydepend
cell
mediat
cytotox
adcc
complement
bind
phagocytosi
recent
technolog
advanc
develop
product
purifi
cation
also
eas
achiev
desir
qualiti
effi
caci
safeti
requir
fda
approv
make
monoclon
antibodi
promis
therapeut
option
thu
monoclon
antibodi
may
prove
use
wnv
prophylaxi
therapi
particularli
elderli
immunocompromis
individu
limit
abil
respond
vaccin
meet
therapeut
goal
control
clinic
trial
therapeut
antibodi
ensur
prophylact
therapeut
effi
caci
along
optim
dose
time
administr
across
rang
patient
group
develop
effect
therapeut
success
treat
mani
viral
diseas
includ
infl
uenza
hepat
c
viru
hcv
hepat
b
viru
hbv
wnv
caus
transient
viremia
human
anim
model
associ
treatment
prevent
approach
wnv
dissemin
brain
develop
sever
diseas
suggest
reduc
viral
load
antivir
drug
earli
phase
infect
may
offer
effi
cient
control
wnv
lessen
chanc
progress
neuroinvas
diseas
addit
antivir
drug
particularli
use
elderli
immunocompromis
patient
may
fail
develop
effi
cient
vaccin
induc
immun
recent
progress
structur
character
wnv
fl
avivirus
broaden
understand
wnv
biolog
provid
foundat
develop
small
molecul
inhibitor
wnv
therapeut
addit
better
understand
pathogenesi
wnv
fl
avivirus
offer
new
opportun
design
mani
differ
class
promis
antivir
therapeut
target
viral
replic
host
cell
metabol
develop
antivir
drug
multistep
process
take
year
reach
market
gener
overview
drug
develop
process
outlin
fig
hittolead
initi
stage
drug
discoveri
small
molecul
hit
screen
evalu
identifi
promis
lead
compound
therapeut
potenti
recent
progress
develop
multipl
approach
design
screen
identifi
cation
valid
hit
compound
review
wit
grow
interest
fi
eld
drug
develop
signifi
cant
progress
structur
function
character
structur
nonstructur
protein
wnv
fl
avivirus
facilit
identifi
cation
therapeut
target
hittolead
screen
exampl
character
pseudoatom
structur
matur
immatur
wnv
atom
resolut
structur
wnv
fl
avivir
protein
xray
crystallographi
nuclear
magnet
reson
nmr
spectroscopi
structur
character
bind
neutral
monoclon
antibodi
e
protein
wnv
greatli
increas
understand
structur
function
aspect
potenti
therapeut
target
two
approach
commonli
use
small
molecul
inhibitor
screen
includ
targetbas
approach
cellbas
approach
targetbas
screen
sever
method
appli
includ
enzym
activitybas
screen
fragmentbas
screen
affi
nitybas
screen
structurebas
ration
contrast
cellbas
approach
use
viral
infect
replic
depend
assay
identifi
inhibitor
approach
present
uniqu
set
merit
challeng
instanc
gener
diffi
cult
identifi
target
also
achiev
specifi
citi
cellbas
assay
identifi
ed
inhibitor
may
potenti
affect
multipl
step
viral
infect
cycl
may
target
viral
host
protein
although
inhibitor
identifi
ed
cellbas
assay
may
prove
use
antivir
drug
candid
compound
could
also
act
nonspecifi
calli
thu
elucid
mechan
action
requir
targetbas
approach
highli
effi
cient
screen
process
howev
inhibitor
screen
method
may
requir
modifi
cation
effect
cellular
permeabl
valid
antivir
activ
select
toxic
use
cellbas
assay
fi
nal
stage
lead
compound
select
vitro
vivo
pharmacokinet
profi
ling
includ
effi
caci
plasma
stabil
halflif
exposur
bioavail
preclin
toxic
plan
clinic
trial
common
strategi
antivir
drug
develop
includ
block
viru
attach
entri
host
cell
inhibit
viral
replic
either
target
viral
compon
host
cell
metabol
signifi
cant
progress
develop
test
potenti
antivir
fl
avivirus
includ
wnv
review
sever
natur
synthet
compound
antivir
peptid
sirna
identifi
ed
target
structur
nonstructur
protein
wnv
evalu
potenti
therapeut
role
approach
includ
target
host
cell
metabol
physiolog
modul
host
immun
system
use
antivir
cytokin
potenti
therapeut
wnv
current
statu
strategi
use
develop
antivir
drug
target
wnv
fl
avivirus
describ
sever
natur
synthet
compound
identifi
ed
target
structur
nonstructur
protein
fl
avivirus
compound
design
target
denv
also
show
antivir
activ
wnv
fl
avivirus
compound
divers
chemistri
discuss
base
mode
action
e
protein
wnv
fl
avivirus
play
key
role
viral
entri
host
cell
mediat
viral
attach
host
cell
receptor
subsequ
membran
fusion
bind
host
cell
receptor
wnv
enter
cell
clathrinindepend
endocytosi
process
follow
lowphdepend
viral
uncoat
endosom
releas
viral
genom
cytoplasm
replic
inhibitor
disrupt
interact
e
protein
cell
receptor
inhibit
membran
fusion
would
potenti
antivir
wnv
two
success
hiv
drug
maraviroc
antagonist
enfuvirtid
peptid
inhibitor
respect
block
viral
entri
membran
fusion
attest
antivir
strategi
fl
avivir
e
glycoprotein
contain
sever
function
site
hydrophob
pocket
receptorbind
domain
stem
domain
may
target
inhibitor
among
hydrophob
ligandbind
pocket
hing
region
domain
ii
e
protein
play
import
role
lowphmedi
membran
fusion
process
uniqu
target
develop
smallmolecul
inhibitor
fl
avivirus
variou
screen
approach
use
identifi
inhibitor
denv
fl
avivirus
bind
hydrophob
pocket
interfer
conform
chang
e
protein
inhibitor
design
test
denv
report
exhibit
antivir
activ
wnv
howev
compound
fail
drug
develop
due
undesir
properti
low
solubl
cytotox
domain
iii
e
glycoprotein
mediat
receptorbind
potenti
target
develop
inhibitor
disrupt
viral
attach
host
cell
receptor
neutral
antibodi
e
protein
proven
potenti
strategi
sever
compound
also
shown
interfer
bind
fl
avivirus
host
cell
receptor
howev
lack
understand
cell
receptor
wnv
hamper
success
approach
identifi
cation
cellular
receptor
wnv
understand
virusreceptor
interact
may
provid
new
opportun
identifi
small
molecul
inhibitor
interrupt
bind
wnv
host
cell
receptor
viral
proteas
essenti
wnv
life
cycl
cleav
viral
polyprotein
precursor
function
protein
success
develop
licens
proteas
inhibitor
hcv
provid
proof
concept
feasibl
similar
target
proteas
virus
ntermin
domain
fl
avivir
amino
acid
serin
proteas
activ
wherea
hydrophob
region
protein
serv
cofactor
activ
enzymat
activ
proteas
wnv
process
viral
polyprotein
precursor
structur
nonstructur
protein
disrupt
activ
lethal
wnv
addit
wnv
proteas
also
cleav
host
protein
may
contribut
neuropathogenesi
recent
progress
express
stabl
identifi
cation
highaffi
niti
substrat
viral
enzym
promot
largescal
dhiraj
acharya
fengwei
bai
screen
proteas
inhibitor
wnv
fl
avivirus
wide
rang
assay
convent
enzymesubstr
base
detect
hplc
elisa
highthroughput
fl
uorescencebas
detect
method
develop
screen
viral
proteas
inhibitor
thu
proteas
attract
target
develop
antivir
wnv
fl
avivirus
review
except
aprotinin
pancreat
trypsin
inhibitor
classic
inhibitor
serin
proteas
inhibit
fl
avivir
proteas
activ
although
aprotinin
potent
inhibitor
fl
avivir
proteas
compound
withdrawn
market
due
safeti
issu
screen
identifi
small
molecul
inhibitor
fl
aviviru
proteas
high
throughput
screen
structurebas
drug
design
use
strategi
base
identifi
cation
alloster
inhibitor
target
interfac
proteas
activ
site
proteas
former
strategi
may
overcom
nonspecifi
citi
latter
due
larg
conserv
activ
site
human
viral
serin
proteinas
number
inhibitor
wnv
proteas
identifi
ed
silico
dock
highthroughput
screen
use
vitro
enzym
activitybas
assay
howev
compound
fail
demonstr
potent
antivir
activ
cell
cultur
although
compound
identifi
ed
approach
show
antiwnv
activ
cellbas
assay
none
inhibitor
progress
beyond
hit
optim
stage
discoveri
proteas
inhibitor
hamper
larg
due
diffi
culti
obtain
cocryst
structur
inhibitorproteas
complex
moreov
weak
bind
affi
niti
activ
site
due
fl
charg
natur
design
potent
small
molecul
inhibitor
structurebas
method
becom
diffi
cult
helicas
enzym
unwind
nucleic
acid
use
energi
deriv
hydrolysi
ntp
ctermin
domain
wnv
contain
helicasenucleas
activ
play
import
role
virul
pathogenesi
high
throughput
assay
measur
helicas
activ
monitor
helicasecatalyz
strand
separ
realtim
use
radioact
fl
uorescentlabel
oligonucleotid
develop
screen
helicas
inhibitor
sever
small
molecul
inhibitor
target
helicas
hcv
develop
use
substratebas
assay
compound
identifi
ed
evalu
vitro
ntpaseshelicas
wnv
fl
avivirus
howev
inhibitori
effect
wnv
helicas
compound
specifi
c
either
dna
rna
substrat
exampl
compound
name
helicasenucleas
inhibitor
treatment
prevent
approach
wnv
tbbt
halogen
benzotriazol
inhibit
helicas
ntpase
activ
seri
ringexpand
nucleosid
nucleotid
analog
ren
also
inhibit
ntpaseshelicas
activ
fl
avivirus
includ
wnv
hcv
jev
howev
compound
show
promis
antiwnv
activ
cell
cultur
nucleosid
analog
imidazo
pyridazin
nucleosid
broadspectrum
antiparasit
drug
name
ivermectin
inhibit
helicas
also
show
antiwnv
activ
cell
cultur
rnadepend
rna
polymeras
rdrp
activ
ctermin
protein
wnv
fl
avivirus
attract
target
develop
antivir
agent
two
approach
use
target
wnv
rdrp
includ
nucleosid
inhibitor
ni
nonnucleosid
inhibitor
nni
ni
also
known
type
inhibitor
nucleosidenucleotid
analog
target
activ
site
polymeras
gener
compet
natur
ntp
substrat
rdrp
block
incorpor
viral
genom
replic
lead
incomplet
replic
mutat
viral
genom
success
ni
sever
virus
includ
herpesvirus
hbv
hcv
alreadi
prove
therapeut
potenti
class
compound
addit
ni
gener
display
broadspectrum
antivir
activ
across
relat
rna
virus
suggest
potenti
panfl
avivir
therapeut
variou
cellbas
cellfre
assay
develop
highthroughput
screen
fl
avivir
rdrp
inhibitor
far
sever
ni
inhibit
wnv
denv
rna
virus
identifi
ed
exampl
favipiravir
relat
compound
select
inhibit
viral
rnadepend
rna
polymeras
potent
antiinfl
uenza
activ
antivir
drug
current
evalu
clinic
trial
infl
uenza
viru
addit
favipiravir
also
block
replic
mani
rna
virus
includ
wnv
promis
drug
candid
broad
rang
rna
viral
diseas
two
nucleosid
analog
call
deriv
triphosph
respect
also
broadspectrum
antivir
compound
target
viral
rdrp
inhibit
denv
hcv
wnv
similarli
two
ni
inhibitor
triphosph
inhibit
four
denv
serotyp
wnv
contrast
ni
inhibitor
antivir
nni
inhibitor
also
known
type
inhibitor
interfer
function
viral
polymeras
occupi
alloster
site
thu
prevent
viral
dhiraj
acharya
fengwei
bai
rna
synthesi
analysi
rdrp
crystal
structur
wnv
reveal
caviti
play
critic
role
viral
replic
suggest
potenti
target
screen
structurebas
alloster
inhibitor
nsulfonylanthranil
acid
deriv
identifi
ed
highthroughput
screen
exampl
alloster
inhibitor
rdrp
activ
denv
howev
compound
specifi
c
denv
show
activ
wnv
rdrp
recent
studi
demonstr
conform
chang
occur
polymeras
bind
inhibitor
howev
similar
antivir
activ
nni
inhibitor
target
polymeras
wnv
report
yet
messeng
rna
mrna
wnv
possess
cap
play
import
role
stabil
mrna
translat
methyltransferas
mtase
activ
ntermin
domain
respons
omethyl
viral
rna
cap
addit
mtase
activ
also
respons
evad
host
antivir
interferon
respons
play
import
role
wnv
pathogenesi
sever
structur
function
studi
along
identifi
cation
sever
potenti
inhibitor
suggest
target
mtase
repres
novel
approach
develop
novel
therapeut
wnv
fl
avivirus
flavivirus
mtase
catalyz
sequenti
methyl
viral
rna
cap
use
sadenosyl
methionin
sam
methyl
donor
contain
singl
bind
site
sam
crystal
structur
addit
mtase
activ
bind
gtp
shown
mtase
domain
sever
member
fl
aviviru
sever
assay
develop
highthroughput
screen
methyltransferas
inhibitor
structuralbas
ligandbas
method
ration
design
sam
analog
identifi
ed
sever
inhibitor
target
mtase
activ
denv
wnv
nonspecifi
c
inhibit
host
mtase
one
potenti
drawback
sam
analog
specifi
c
inhibit
fl
avivir
host
mtase
achiev
target
pocket
near
sambind
site
two
nucleosid
analog
identifi
ed
potent
inhibit
mtase
wnv
without
inhibit
human
mtase
one
compound
show
antivir
activ
wnv
cell
cultur
addit
sever
screen
studi
yfv
denv
identifi
ed
hit
target
mtase
activ
show
antivir
activ
wnv
cell
cultur
howev
extens
multistag
molecular
dock
approach
screen
librari
million
commerci
compound
two
activ
site
denv
mtasegtas
fail
identifi
specifi
c
hit
recent
nucleosid
scaffold
deriv
azt
demonstr
antivir
activ
wnv
denv
bind
mtase
sever
potenti
tool
includ
ration
design
phase
display
librari
develop
highthroughput
screen
specifi
c
antivir
peptid
enfuvirtid
peptid
base
stem
region
hiv
exemplifi
es
effi
cient
antivir
peptid
current
clinic
use
thu
antivir
peptid
may
serv
novel
therapeut
measur
wnv
sever
antivir
peptid
target
structur
nonstructur
protein
wnv
fl
aviviru
identifi
ed
target
wnv
e
protein
antivir
peptid
potenti
strategi
block
viru
attach
entri
host
cell
sever
short
antivir
peptid
amino
acid
residu
bind
wnv
e
protein
identifi
ed
screen
murin
brain
cdna
phage
display
librari
one
peptid
reduc
viremia
fatal
wnv
infect
mice
effi
cientli
penetr
murin
bloodbrain
barrier
impli
may
antivir
activ
cn
similarli
peptid
inhibitor
target
domain
ii
wnv
e
protein
design
use
physicochem
algorithm
approach
potent
inhibit
wnv
infect
anoth
peptid
design
target
domain
ii
denv
e
show
antivir
activ
denv
wnv
addit
ration
drug
design
approach
use
identifi
peptidomimet
mimic
proteas
substrat
inhibit
activ
mechan
propos
peptidomimet
cleav
p
p
peptid
substrat
consist
p
p
p
p
p
basic
amino
acid
arg
ly
sidechain
amino
acid
gli
ser
ala
thu
prefer
peptid
substrat
contain
sever
posit
charg
amino
acid
common
method
screen
peptid
inhibitor
proteas
employ
fl
uorophor
conjug
peptid
substrat
contain
basic
amino
acid
posit
cleavag
peptid
substrat
proteas
result
releas
fl
uorophor
increas
fl
uoresc
sever
peptid
inhibitor
proteas
identifi
ed
wnv
novel
agmatin
dipeptid
inhibitor
improv
inhibitori
activ
wnv
recent
identifi
ed
addit
recombin
peptid
call
shown
inhibit
proteas
howev
peptid
show
poor
activ
cellbas
assay
test
vivo
effi
caci
thu
peptid
inhibitor
proteas
identifi
ed
far
fail
earli
develop
stage
potenti
limit
approach
includ
poor
pharmacokinet
properti
due
charg
natur
peptid
lack
specifi
citi
requir
intraven
deliveri
rapid
degrad
plasma
costli
product
dhiraj
acharya
fengwei
bai
rna
interfer
rnai
cellular
process
fi
rst
describ
nematod
caenorhabd
elegan
process
specif
degrad
rna
sequencespecifi
c
manner
conserv
mammalian
cell
rnai
natur
defens
eukaryot
cell
viral
infect
may
promis
strategi
develop
potenti
antivir
therapeut
numer
sirna
target
identifi
ed
genom
region
wnv
encod
structur
nonstructur
protein
sirna
target
protein
effect
inhibit
wnv
replic
besid
sirna
target
code
region
sirna
target
noncod
region
also
identifi
ed
inhibit
wnv
replic
sequencespecifi
c
manner
although
antiwnv
sirna
effi
cientli
block
viral
replic
cell
cultur
similar
success
diffi
cult
achiev
anim
model
quick
degrad
serum
nucleas
failur
reach
target
cell
rapid
renal
excret
due
small
size
anion
charact
hinder
clinic
applic
antivir
sirna
sever
deliveri
system
includ
cellpenetr
peptid
nanoparticl
viral
vector
may
improv
sirna
stabil
enhanc
deliveri
effi
cienci
despit
mani
challeng
use
antivir
sirna
antiwnv
therapeut
remain
promis
cytokin
signal
control
divers
immun
function
infect
autoimmun
diseas
cancer
variou
immunomodulatori
immunostimulatori
cytokin
chemokin
identifi
ed
play
protect
patholog
role
wnv
infect
exampl
typei
interferon
ifn
interleukin
il
macrophag
migrat
inhibitori
factor
mif
protect
wnv
infect
wherea
favor
wnv
pathogen
pharmacolog
blockad
neutral
antibodi
shown
protect
mice
wnv
challeng
type
ifn
inhibit
mani
fl
avivirus
includ
wnv
use
therapeut
hepat
c
viru
although
therapeut
effect
type
ifn
wnv
yet
evalu
applic
may
limit
due
antagonist
role
wnv
protein
ifn
signal
interestingli
treatment
pegyl
also
known
type
iii
interferon
recent
shown
protect
mice
lethal
wnv
infect
decreas
bloodbrain
barrier
permeabl
thu
strategi
target
express
cytokin
chemokin
block
signal
direct
use
recombin
cytokin
may
novel
approach
treat
wnv
infect
control
patholog
virus
util
host
cellular
system
entri
genom
replic
transcript
synthesi
viral
protein
product
viral
progeni
addit
interact
viral
protein
cellular
protein
may
evad
host
immun
defens
favor
viral
replic
pathogenesi
sever
host
pathway
enzym
includ
clathrinmedi
endocytosi
cyclophilin
ubiquitinproteasom
system
unfold
protein
respons
nucleotid
biosynthesi
posttransl
protein
modifi
cation
lipid
metabol
suggest
fl
aviviru
replic
pathogenesi
target
host
factor
may
use
strategi
develop
antivir
therapeut
fl
avivirus
includ
wnv
infect
far
mani
inhibitor
target
host
protein
develop
test
wnv
fl
avivirus
hcv
host
cyclophilin
famili
cellular
peptidylprolyl
isomeras
may
serv
compon
fl
aviviru
replic
complex
play
role
fl
avivir
replic
target
enzym
cyclosporin
inhibit
replic
wnv
target
lipid
signal
metabol
bioactiv
lipid
signal
modul
retinamid
fenretinid
also
inhibit
replic
wnv
fl
avivirus
similarli
ribavirin
mycophenol
acid
target
inosin
monophosph
dehydrogenas
impdh
enzym
purin
biosynthesi
therebi
inhibit
replic
fl
avivirus
addit
brequinar
block
pyrimidin
biosynthesi
also
inhibit
replic
broad
rang
rna
virus
includ
wnv
fl
avivirus
besid
block
viral
genom
replic
antivir
target
step
viru
matur
assembl
viral
dissemin
brain
also
suggest
test
wnv
instanc
inhibitor
alphaglucosidas
ii
enzym
play
role
process
nlink
oligosaccharid
viral
glycoprotein
also
inhibit
wnv
fl
avivirus
although
mechan
wnv
enter
brain
still
poorli
understood
two
potenti
rout
includ
axon
retrograd
transport
art
peripher
nervou
system
direct
hematogen
diffus
via
breakdown
bloodchoroid
plexu
barrier
nocodazol
microtubul
inhibitor
block
art
delay
wnv
entri
brain
termin
stemloop
fl
avivir
rna
contain
essenti
cisact
element
play
import
role
viral
replic
interestingli
rang
cellular
protein
identifi
ed
interact
stemloop
fl
avivir
rna
suggest
potenti
strategi
design
inhibitor
target
virushost
protein
interact
target
host
factor
may
rais
higher
barrier
viral
resist
emerg
provid
broadspectrum
antivir
effect
howev
current
understand
virushost
cell
interact
research
target
host
factor
block
viral
infect
still
limit
addit
potenti
drawback
approach
includ
undesir
druginduc
sideeffect
diffi
culti
drug
deliveri
brain
control
wnv
enceph
understand
virushost
interact
facilit
identifi
cation
novel
antivir
agent
develop
test
variou
method
treatment
prevent
wnv
infect
protect
vaccin
therapeut
antibodi
antivir
compound
peptid
sirna
propos
intens
studi
although
number
wnv
veterinari
vaccin
alreadi
licens
use
year
human
vaccin
candid
still
variou
stage
develop
test
therapeut
antibodi
show
excel
effi
caci
small
anim
model
current
test
clinic
trial
repres
promis
class
wnv
therapeut
recent
technolog
advanc
increas
understand
biolog
wnv
fl
avivirus
along
structuralfunct
character
viral
protein
provid
solid
foundat
develop
small
molecul
inhibitor
futur
wnv
therapeut
howev
effort
develop
effect
drug
prevent
control
wnv
infect
human
still
remain
unsuccess
reason
includ
low
incid
diseas
low
commerci
interest
pharmaceut
compani
high
cost
mass
vaccin
diffi
culti
run
clinic
trial
due
unpredict
sporad
natur
wnv
outbreak
anoth
challeng
develop
success
wnv
therapeut
ensur
safeti
effi
caci
target
popul
mostli
includ
children
elderli
immunecompromis
individu
despit
diffi
culti
quest
develop
effect
treatment
prevent
method
wnv
infect
like
facilit
recent
technolog
advanc
continu
meet
public
health
need
